The European Medicines Agency didn't specify which additional GLP-1 drugs are now being investigated, but it could potentially include Eli Lilly's Mounjaro.
flagged three cases of suicidal thoughts and self-injury in patients taking drugs containing liraglutide and semaglutide.
Liraglutide and semaglutide are part of a class of highly popular drugs called GLP-1 receptor agonists. Novo Nordisk said in a statement to CNBC on Monday that "safety data collected from large clinical trial programs and post marketing surveillance have not demonstrated a causal association between semaglutide or liraglutide and suicidal and self-harming thoughts."
The EMA's investigation could potentially establish new side effects associated with blockbuster drugs like Wegovy and Ozempic, which are already known to cause nausea, vomiting and diarrhea.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
European drugs regulator to review Wegovy, Ozempic following reports of suicidal thoughtsDanish firm Novo Nordisk says “patient safety is a top priority” following reports.
Leer más »
Popular weight loss drug gets new warningWegovy and Ozempic are brand names for a drug called semaglutide.
Leer más »
Beyond Wegovy: Could the next wave of weight-loss drugs end obesity?Wegovy and Ozempic have made headlines, but a new wave of more effective drugs like Mounjaro have the potential to end obesity altogether. How will they work and are they safe?
Leer más »
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harmThe European Medicines Agency said Tuesday it’s reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines...
Leer más »
EU extends Ozempic review to include more weight-loss, diabetes drugsThe European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk's diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class.
Leer más »
A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On ItFractyl Health is developing a gene therapy alternative to drugs like Ozempic and Wegovy to control blood sugar and body weight without repeated injections.
Leer más »